Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Autologous stem cell transplant in ALL: who should we be transplanting in first remission?

Bone Marrow Transplantation volume 37, pages 989–995 (2006)Cite this article

Abstract

Long-term disease-free survival (DFS) has been reported after autologous stem cell transplantation for acute lymphoblastic leukemia. Phase II studies have evaluated its role in first and subsequent complete remission (CR) with DFS rates of up to 50%. It has been under-utilized in 1st CR in part, due to a concern that patients who relapse after autologous stem cell transplantation (ASCT) have fewer options for salvage treatment of relapsed disease. Unfortunately, survival rates of <5% are reported in patients who relapse, regardless of initial therapy. Few prospective, randomized trials have analyzed large enough numbers of patients to allow us to determine the appropriate patient population for autologous transplantation. Although variability in the available studies makes it difficult to draw a definite conclusion, and many issues remain unresolved, available data suggests that there may be a group of patients for whom ASCT in first remission is a reasonable and perhaps superior treatment choice. Factors such as risk features at diagnosis, and minimal residual disease following induction therapy greatly affect outcome following ASCT. The available data as well as the questions that remain to be answered will be discussed and reviewed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2005; 11: 823–861.

    Article  PubMed  Google Scholar 

  2. McGovern Jr JJ, Russell PS, Atkins L, Webster EW . Treatment of terminal leukemic relapse by total-body irradiation and intravenous infusion of stored autologous bone marrow obtained during remission. N Engl J Med 1959; 260: 675–683.

    Article  PubMed  Google Scholar 

  3. Fiere D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant JP et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1993; 11: 1990–2001.

    Article  CAS  PubMed  Google Scholar 

  4. Gorin NC, Aegerter P, Auvert B . Autologous bone marrow transplantation for acute leukemia in remission: an analysis of 1322 cases. Haematol Blood Transfus 1990; 33: 660–666.

    CAS  PubMed  Google Scholar 

  5. Tiley C, Powles R, Treleaven J, Catovsky D, Milan S, Teo CP et al. Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia. Bone Marrow Transplant 1993; 12: 449–455.

    CAS  PubMed  Google Scholar 

  6. Blaise D, Attal M, Pico JL, Reiffers J, Stoppa AM, Bellanger C et al. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leuk Lymphoma 1997; 25: 469–478.

    Article  CAS  PubMed  Google Scholar 

  7. Simonsson B, Burnett AK, Prentice HG, Hann IH, Brenner MK, Gibson B et al. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia 1989; 3: 631–636.

    CAS  PubMed  Google Scholar 

  8. Doney K, Buckner CD, Fisher L, Petersen FB, Sanders J, Appelbaum FR et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant 1993; 12: 315–321.

    CAS  PubMed  Google Scholar 

  9. Carey PJ, Proctor SJ, Taylor P, Hamilton PJ . Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. Blood 1991; 77: 1593–1598.

    CAS  PubMed  Google Scholar 

  10. Lambertenghi Deliliers G, Mozzana R, Annaloro C, Butti C, Della Volpe A, Oriani A et al. Long-term results of autologous bone marrow transplantation in adult acute lymphoblastic leukemia. Leuk Lymphoma 1993; 11: 419–425.

    Article  CAS  PubMed  Google Scholar 

  11. Gilmore MJ, Hamon MD, Prentice HG, Katz F, Slaper-Cortenbach IC, Hunter AE et al. Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission. Bone Marrow Transplant 1991; 8: 19–26.

    CAS  PubMed  Google Scholar 

  12. Vey N, Blaise D, Stoppa AM, Bouabdallah R, Lafage M, Sainty D et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1994; 14: 383–388.

    CAS  PubMed  Google Scholar 

  13. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075–4086.

    Article  CAS  PubMed  Google Scholar 

  14. Jabbour EJ, Faderl S, Kantarjian HM . Adult acute lymphoblastic leukemia. Mayo Clin Proc 2005; 80: 1517–1527.

    Article  CAS  PubMed  Google Scholar 

  15. Bassan R, Lerede T, Di Bona E, Rambaldi A, Rossi G, Pogliani E et al. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia. Br J Haematol 1999; 104: 755–762.

    Article  CAS  PubMed  Google Scholar 

  16. Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004; 104: 3028–3037.

    Article  CAS  PubMed  Google Scholar 

  17. Gorin NC . Autologous stem cell transplantation in acute lymphocytic leukemia. Stem Cells 2002; 20: 3–10.

    Article  CAS  PubMed  Google Scholar 

  18. Powles R, Sirohi B, Treleaven J, Kulkarni S, Tait D, Singhal S et al. The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 2002; 100: 1641–1647.

    Article  CAS  PubMed  Google Scholar 

  19. Hallbook H, Hagglund H, Stockelberg D, Nilsson PG, Karlsson K, Bjorkholm M et al. Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience. Bone Marrow Transplant 2005; 35: 1141–1148.

    Article  CAS  PubMed  Google Scholar 

  20. Egerer G, Goldschmidt H, Zoz M, Ho AD . Autologous bone marrow transplantation in adult patients with acute lymphoblastic leukemia. Leuk Lymphoma 2003; 44: 9–14.

    Article  CAS  PubMed  Google Scholar 

  21. Martin H, Atta J, Zumpe P, Eder M, Elsner S, Rode C et al. Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia. Exp Hematol 1995; 23: 1612–1618.

    CAS  PubMed  Google Scholar 

  22. Uckun FM, Kersey JH, Vallera DA, Ledbetter JA, Weisdorf D, Myers DE et al. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723–1733.

    CAS  PubMed  Google Scholar 

  23. Uckun FM, Kersey JH, Haake R, Weisdorf D, Ramsay NK . Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging. Blood 1992; 79: 1094–1104.

    CAS  PubMed  Google Scholar 

  24. Uckun FM, Myers DE . Allograft and autograft purging using immunotoxins in clinical bone marrow transplantation for hematologic malignancies. J Hematother 1993; 2: 155–163.

    Article  CAS  PubMed  Google Scholar 

  25. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer – Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591–598.

    Article  CAS  PubMed  Google Scholar 

  26. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691–2696.

    CAS  PubMed  Google Scholar 

  27. Chen JS, Coustan-Smith E, Suzuki T, Neale GA, Mihara K, Pui CH et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001; 97: 2115–2120.

    Article  CAS  PubMed  Google Scholar 

  28. Morishima Y, Miyamura K, Kojima S, Ueda R, Morishita Y, Sao H et al. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement. Bone Marrow Transplant 1993; 11: 255–259.

    CAS  PubMed  Google Scholar 

  29. Mizuta S, Ito Y, Kohno A, Kiyoi H, Miyamura K, Tanimoto M et al. Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group. Bone Marrow Transplant 1999; 24: 777–784.

    Article  CAS  PubMed  Google Scholar 

  30. Foroni L, Mitchell W, Rai LJ, Casanova A, Patel B, Richards S et al. Value of Molecular Monitoring for Minimal Residual Disease Preceding Autologous SCT Following Diagnosis of B Cell Acute Lymphoblastic Leukemia in Patients Treated with the MRC UKALL12 Protocol. Blood 2005; 106: 423a (Abstract 1468).

    Google Scholar 

  31. Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia – results of the prospective multicenter LALA-94 trial. Blood 2002; 100: 2357–2366.

    Article  CAS  PubMed  Google Scholar 

  32. Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gokbuget N, Atta J et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Blood 2004; 103: 1495–1498.

    Article  CAS  PubMed  Google Scholar 

  33. Thiebaut A, Vernant JP, Degos L, Huguet FR, Reiffers J, Sebban C et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000; 14: 1353–1366.

    Article  CAS  PubMed  Google Scholar 

  34. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM et al. Induction therapy for adults with acute lymphoblastic leukemia (ALL): Results of nearly 1,400 patients from the international ALL trial (MRC UKALL XII/ECOG E2993). Blood 2003; 102: 224a (Abstract 785).

  35. Goldstone AH, Lazarus JH, Richards SM, Litzow MR, Chopra R, Burnett A et al. The Outcome of 551 1st CR Transplants in Adult ALL from the UKALL XII/ECOG 2993 Study. Blood 2004; 104: 178a (Abstract 615).

    Article  Google Scholar 

  36. Goldstone AH, Chopra R, Buck G, Richards M, Franklin IM, Lazarus HM et al. The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years. Blood 2003; 102: 80a (Abstract 268).

  37. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Singhal S . High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 2004; 33: 1107–1114.

    Article  CAS  PubMed  Google Scholar 

  38. Singhal S, Powles R, Treleaven J, Kulkarni S, Horton C, Tait D et al. Sequential high-dose therapy of adult acute lymphoblastic leukemia: Blood cell autografts with maintenance therapy in first remission and allografting in second remission for relapsing patients. Blood 1996; 88: 125a (Abstract 490).

  39. Ringden O, Labopin M, Gorin NC, Meloni G, Blaise D, Reiffers J et al. The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2000; 25: 1053–1058.

    Article  CAS  PubMed  Google Scholar 

  40. Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999; 86: 1216–1230.

    Article  CAS  PubMed  Google Scholar 

  41. Chopra R, Goldstone AH, Buck G, Richards SM, Franklin I, Lazarus HM et al. Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 Trial. Blood 2003; 102: 880a (Abstract 3275).

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Internal Medicine, Hematologic Malignancies Program, University of Pennsylvania Medical Center, Philadelphia, PA, USA

    A R Mato & S M Luger

Authors
  1. A R Mato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S M Luger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S M Luger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mato, A., Luger, S. Autologous stem cell transplant in ALL: who should we be transplanting in first remission?. Bone Marrow Transplant 37, 989–995 (2006). https://doi.org/10.1038/sj.bmt.1705370

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705370

Keywords

This article is cited by

Search

Advanced search

Quick links